|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
North Suffolk Mental Health Association |
|---|---|
| Information provided by: | North Suffolk Mental Health Association |
| ClinicalTrials.gov Identifier: | NCT00320723 |
Purpose
This proposal seeks to evaluate a pilot smoking cessation treatment program that will combine nicotine replacement therapy with or without bupropion sustained-release (SR) with cognitive behavioral therapy for smoking cessation in patients with major mental illness.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia Schizoaffective Disorder |
Drug: bupropion, transdermal nicotine patch |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness |
| Estimated Enrollment: | 100 |
| Study Start Date: | July 2001 |
| Estimated Study Completion Date: | December 2005 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, Massachusetts | |
| Freedom Trail Clinic | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | A Eden Evins, MD, MPH | North Suffolk Mental Health Association |
More Information
| Responsible Party: | Massachusetts General Hospital ( A Eden Evins, MD, MPH ) |
| Study ID Numbers: | DMH CORRC 20-01 |
| Study First Received: | April 28, 2006 |
| Last Updated: | May 15, 2009 |
| ClinicalTrials.gov Identifier: | NCT00320723 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
schizophrenia smoking cessation nicotine patch |
bupropion nicotine replacement therapy cognitive behavioral therapy |
|
Dopamine Uptake Inhibitors Nicotine polacrilex Neurotransmitter Agents Nicotinic Agonists Psychotropic Drugs Central Nervous System Stimulants Cholinergic Agents Schizophrenia Smoking Dopamine |
Mental Disorders Nicotine Bupropion Dopamine Agents Psychotic Disorders Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Antidepressive Agents Schizophrenia and Disorders with Psychotic Features |
|
Nicotine polacrilex Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Nicotinic Agonists Physiological Effects of Drugs Psychotropic Drugs Cholinergic Agents Schizophrenia Nicotine Mental Disorders |
Therapeutic Uses Ganglionic Stimulants Psychotic Disorders Antidepressive Agents, Second-Generation Schizophrenia and Disorders with Psychotic Features Antidepressive Agents Central Nervous System Stimulants Pharmacologic Actions Autonomic Agents Bupropion Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |